Fed. Circ. Urged To End 'Unrealistic' Obviousness Test
A biotech trade group is urging the Federal Circuit to use a patent case involving Amarin Pharma's blockbuster heart drug Vascepa to end the court's "unrealistic" approach to determining whether a...To view the full article, register now.
Already a subscriber? Click here to view full article